US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kairos Pharma, Ltd.

0.3500

0.0000

Volume:250.76K

Turnover:87.30K

Market Cap:7.49M

PE:-1.18

High:0.3597

Open:0.3450

Low:0.3400

Close:0.3500

52wk High:2.11

52wk Low:0.2695

Shares:21.41M

Float Shares:11.81M

Volume Ratio:0.47

T/O Rate:2.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2972

EPS(LYR):-0.2956

ROE:-93.84%

ROA:-54.78%

PB:1.41

PE(LYR):-1.18

Loading ...

Overview Company News Filings

Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12

Analysts Offer Insights on NA Companies: James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (KAPA)

Kairos Pharma, Bayer partner on prostate cancer therapy

Kairos Pharma Partners with Bayer to Test Env-105 with Xofigo in Metastatic Prostate Cancer

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance Xofigo Activity in Metastatic Prostate Cancer

THOMSON REUTERS

Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105

Kairos Pharma Says Phase 1 Env-105 Plus Tagrisso Trial Shows no Grade 3+ Toxicities in 13 Patients

Kairos Pharma - no Grade 3 or Higher Adverse Events Observed in 13 Patients Treated with Env-105

THOMSON REUTERS

Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of Env-105 in Egfr-mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market

THOMSON REUTERS

Kairos Pharma Holds Annual Shareholder Meeting, Approves Reverse Stock Split Authorization

Kairos Pharma outlines mid-year oncology pipeline and funding plans

Kairos Pharma issues letter from CEO that recaps year, details plans for 2026

Kairos Pharma signs term sheet to acquire worldwide rights to Celyn Therapeutics’ CL-741 cancer drug candidate

Kairos Pharma says shareholder letter now available to investors

Kairos Pharma Highlights Clinical Programs at LD Micro

Analysts Offer Insights on Healthcare Companies: Kairos Pharma, Ltd. (KAPA), Integra Lifesciences (IART) and Biogen (BIIB)

Kairos Pharma Q1 net loss widens to $1.65 million; no revenue

Kairos Pharma announces annual shareholder meeting

Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Actinium Pharmaceuticals (ATNM)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KAPA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KAPA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","market":"US","secType":"STK","nameCN":"Kairos Pharma, Ltd.","latestPrice":0.35,"timestamp":1786467081253,"preClose":0.35,"halted":0,"volume":250760,"delay":0,"changeRate":0,"floatShares":11814300,"shares":21411198,"eps":-0.297176,"marketStatus":"Trading","change":0,"latestTime":"08-11 12:51:45 EDT","open":0.345,"high":0.3597,"low":0.34,"amount":87301.34172,"amplitude":0.056286,"askPrice":0.3629,"askSize":500,"bidPrice":0.3481,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.297176,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786478400000},"marketStatusCode":2,"adr":0,"listingDate":1717992000000,"exchange":"AMEX","adjPreClose":0.35,"preHourTrading":{"tag":"盘前","latestPrice":0.3498,"preClose":0.35,"latestTime":"09:12 EDT","volume":17237,"amount":5989.89076741,"timestamp":1786453965644,"change":-0.0002,"changeRate":-0.000571,"amplitude":0.036286},"postHourTrading":{"tag":"盘后","latestPrice":0.3517,"preClose":0.35,"latestTime":"19:57 EDT","volume":46488,"amount":16295.4572,"timestamp":1786406265277,"change":0.0017,"changeRate":0.004857,"amplitude":0.026},"volumeRatio":0.468198},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","floatShares":11814300,"roa":"-54.78%","roe":"-93.84%","lyrEps":-0.295586,"volumeRatio":0.468198,"shares":21411198,"dividePrice":0,"high":0.3597,"amplitude":0.056286,"preClose":0.35,"low":0.34,"week52Low":0.2695,"pbRate":"1.41","week52High":2.11,"institutionHeld":0,"latestPrice":0.35,"eps":-0.297176,"divideRate":0,"volume":250760,"delay":0,"ttmEps":-0.297176,"open":0.345,"prevYearClose":0.71,"prevWeekClose":0.386,"prevMonthClose":0.3061,"prevQuarterClose":0.3837,"fiveDayClose":0.3252,"twentyDayClose":0.34,"sixtyDayClose":0.4923},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KAPA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KAPA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KAPA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743912000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KAPA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KAPA","date":"2026-08-10","current":-1.177753,"percent":0.943038,"low":-25.607053,"twenty":-7.030345,"median":-4.367964,"eighty":-2.401038,"high":-1.092378,"avg":-4.728172,"sd":3.007176,"marketCap":8264722},"quantilePoints":[{"date":"2024-09-13","current":-25.607053,"twenty":-25.607053,"median":-25.607053,"eighty":-25.607053,"marketCap":51367748},{"date":"2024-09-20","current":-14.59602,"twenty":-25.607053,"median":-16.196461,"eighty":-14.724055,"marketCap":29279616},{"date":"2024-09-27","current":-10.594918,"twenty":-16.644584,"median":-14.59602,"eighty":-12.803526,"marketCap":21253405},{"date":"2024-10-04","current":-8.706398,"twenty":-15.748337,"median":-12.835535,"eighty":-9.858715,"marketCap":17465034},{"date":"2024-10-11","current":-9.410592,"twenty":-14.724055,"median":-10.594918,"eighty":-8.706398,"marketCap":18877647},{"date":"2024-10-18","current":-9.410592,"twenty":-14.59602,"median":-9.890724,"eighty":-9.026486,"marketCap":18877647},{"date":"2024-10-25","current":-9.602645,"twenty":-14.019861,"median":-9.73068,"eighty":-9.026486,"marketCap":19262905},{"date":"2024-10-31","current":-8.64238,"twenty":-13.098007,"median":-9.602645,"eighty":-8.947104,"marketCap":17336614},{"date":"2024-11-08","current":-8.770415,"twenty":-12.81633,"median":-9.464686,"eighty":-8.64238,"marketCap":17593453},{"date":"2024-11-15","current":-13.158824,"twenty":-13.152678,"median":-9.474609,"eighty":-8.64238,"marketCap":26396601},{"date":"2024-11-22","current":-7.030345,"twenty":-12.924264,"median":-9.410592,"eighty":-8.578362,"marketCap":19270177},{"date":"2024-11-29","current":-7.217821,"twenty":-12.829133,"median":-9.282556,"eighty":-8.469532,"marketCap":19784048},{"date":"2024-12-06","current":-6.608525,"twenty":-12.265778,"median":-9.026486,"eighty":-7.967725,"marketCap":18113966},{"date":"2024-12-13","current":-8.061463,"twenty":-11.119862,"median":-8.738406,"eighty":-7.667763,"marketCap":22096470},{"date":"2024-12-20","current":-7.920856,"twenty":-10.268428,"median":-8.706398,"eighty":-7.780249,"marketCap":21711066},{"date":"2024-12-27","current":-7.827118,"twenty":-9.999554,"median":-8.64238,"eighty":-7.780249,"marketCap":21454130},{"date":"2025-01-03","current":-7.170953,"twenty":-9.909929,"median":-8.578362,"eighty":-7.46154,"marketCap":19655581},{"date":"2025-01-10","current":-4.827504,"twenty":-9.858715,"median":-8.578362,"eighty":-7.311559,"marketCap":13232188},{"date":"2025-01-17","current":-8.295808,"twenty":-9.858715,"median":-8.530349,"eighty":-7.261949,"marketCap":22738809},{"date":"2025-01-24","current":-7.311559,"twenty":-9.756287,"median":-8.373067,"eighty":-7.264142,"marketCap":20040984},{"date":"2025-01-31","current":-6.936607,"twenty":-9.73068,"median":-8.108332,"eighty":-7.170953,"marketCap":19013241},{"date":"2025-02-07","current":-6.749132,"twenty":-9.628252,"median":-8.036517,"eighty":-7.161579,"marketCap":18499370},{"date":"2025-02-14","current":-6.796001,"twenty":-9.602645,"median":-7.967725,"eighty":-7.030345,"marketCap":18627838},{"date":"2025-02-21","current":-6.233573,"twenty":-9.526207,"median":-7.967725,"eighty":-7.030345,"marketCap":17086224},{"date":"2025-02-28","current":-5.671145,"twenty":-9.474865,"median":-7.897422,"eighty":-6.869431,"marketCap":15544609},{"date":"2025-03-07","current":-5.198227,"twenty":-9.462702,"median":-7.803684,"eighty":-6.730384,"marketCap":14248340},{"date":"2025-03-14","current":-4.773372,"twenty":-9.428261,"median":-7.780249,"eighty":-6.44917,"marketCap":13083812},{"date":"2025-03-21","current":-4.898329,"twenty":-9.410592,"median":-7.639642,"eighty":-6.289816,"marketCap":13426320},{"date":"2025-03-28","current":-4.848346,"twenty":-9.33377,"median":-7.452166,"eighty":-6.092966,"marketCap":13289317},{"date":"2025-04-04","current":-4.698397,"twenty":-9.282556,"median":-7.358428,"eighty":-5.577408,"marketCap":12878307},{"date":"2025-04-11","current":-4.948312,"twenty":-9.244146,"median":-7.311559,"eighty":-5.297393,"marketCap":13563323},{"date":"2025-04-17","current":-4.775903,"twenty":-9.141718,"median":-7.263319,"eighty":-5.121191,"marketCap":12431676},{"date":"2025-04-25","current":-5.470376,"twenty":-9.018804,"median":-7.217821,"eighty":-5.172643,"marketCap":14239390},{"date":"2025-05-02","current":-5.034285,"twenty":-8.912535,"median":-7.170953,"eighty":-5.172643,"marketCap":13104245},{"date":"2025-05-09","current":-4.841892,"twenty":-8.744808,"median":-7.124084,"eighty":-5.140524,"marketCap":12603446},{"date":"2025-05-16","current":-2.898471,"twenty":-8.706398,"median":-7.030345,"eighty":-5.053706,"marketCap":10266383},{"date":"2025-05-23","current":-2.643971,"twenty":-8.706398,"median":-7.030345,"eighty":-4.968305,"marketCap":9364944},{"date":"2025-05-30","current":-2.626341,"twenty":-8.693594,"median":-6.936607,"eighty":-4.902727,"marketCap":9302501},{"date":"2025-06-06","current":-2.390394,"twenty":-8.64238,"median":-6.865004,"eighty":-4.843183,"marketCap":8466776},{"date":"2025-06-13","current":-2.711492,"twenty":-8.629576,"median":-6.796001,"eighty":-4.780395,"marketCap":9604104},{"date":"2025-06-20","current":-2.911286,"twenty":-8.578362,"median":-6.702263,"eighty":-4.758377,"marketCap":10311775},{"date":"2025-06-27","current":-3.282332,"twenty":-8.578362,"median":-6.467918,"eighty":-4.698397,"marketCap":11626021},{"date":"2025-07-03","current":-3.096809,"twenty":-8.578362,"median":-6.421049,"eighty":-4.598431,"marketCap":10968898},{"date":"2025-07-11","current":-3.382229,"twenty":-8.578362,"median":-6.327311,"eighty":-4.315248,"marketCap":11979856},{"date":"2025-07-18","current":-4.852143,"twenty":-8.578362,"median":-6.210138,"eighty":-4.078861,"marketCap":17186292},{"date":"2025-07-25","current":-4.424013,"twenty":-8.501541,"median":-6.156578,"eighty":-4.315248,"marketCap":15669854},{"date":"2025-08-01","current":-4.281779,"twenty":-8.456729,"median":-5.830571,"eighty":-4.144691,"marketCap":15166060},{"date":"2025-08-08","current":-4.566723,"twenty":-8.326712,"median":-5.698056,"eighty":-4.256377,"marketCap":16175333},{"date":"2025-08-15","current":-5.460044,"twenty":-8.265781,"median":-5.577408,"eighty":-4.144691,"marketCap":25722268},{"date":"2025-08-22","current":-5.151816,"twenty":-8.175816,"median":-5.56016,"eighty":-4.256377,"marketCap":24270205},{"date":"2025-08-29","current":-5.548109,"twenty":-8.117706,"median":-5.504045,"eighty":-4.350727,"marketCap":26137143},{"date":"2025-09-05","current":-6.825055,"twenty":-8.080211,"median":-5.554134,"eighty":-4.371339,"marketCap":32152835},{"date":"2025-09-12","current":-7.925871,"twenty":-8.146034,"median":-5.577408,"eighty":-4.403843,"marketCap":37338777},{"date":"2025-09-19","current":-5.90037,"twenty":-8.123413,"median":-5.684601,"eighty":-4.424013,"marketCap":27796645},{"date":"2025-09-26","current":-5.019718,"twenty":-8.080211,"median":-5.577408,"eighty":-4.452555,"marketCap":23647892},{"date":"2025-10-03","current":-5.063751,"twenty":-8.031527,"median":-5.554134,"eighty":-4.485854,"marketCap":23855329},{"date":"2025-10-10","current":-5.812305,"twenty":-7.985263,"median":-5.56016,"eighty":-4.525921,"marketCap":27381769},{"date":"2025-10-17","current":-5.151816,"twenty":-7.967725,"median":-5.531688,"eighty":-4.55855,"marketCap":24270205},{"date":"2025-10-24","current":-4.799555,"twenty":-7.967725,"median":-5.492822,"eighty":-4.58125,"marketCap":22610703},{"date":"2025-10-31","current":-5.019718,"twenty":-7.967725,"median":-5.46521,"eighty":-4.595432,"marketCap":23647892},{"date":"2025-11-07","current":-3.830837,"twenty":-7.967725,"median":-5.399832,"eighty":-4.525921,"marketCap":18047075},{"date":"2025-11-14","current":-3.48298,"twenty":-7.942613,"median":-5.371979,"eighty":-4.424013,"marketCap":16408318},{"date":"2025-11-21","current":-2.82458,"twenty":-7.922862,"median":-5.327946,"eighty":-4.230974,"marketCap":14298023},{"date":"2025-11-28","current":-3.42923,"twenty":-7.902108,"median":-5.296194,"eighty":-4.097795,"marketCap":17358761},{"date":"2025-12-05","current":-3.740193,"twenty":-7.855239,"median":-5.283914,"eighty":-3.903739,"marketCap":18932856},{"date":"2025-12-12","current":-3.331745,"twenty":-7.817744,"median":-5.203591,"eighty":-3.780288,"marketCap":16865295},{"date":"2025-12-19","current":-3.187781,"twenty":-7.79431,"median":-5.197038,"eighty":-3.655562,"marketCap":16136548},{"date":"2025-12-26","current":-3.052866,"twenty":-7.780249,"median":-5.190491,"eighty":-3.531486,"marketCap":15453608},{"date":"2026-01-02","current":-2.920419,"twenty":-7.780249,"median":-5.153702,"eighty":-3.48298,"marketCap":14783160},{"date":"2026-01-09","current":-3.989868,"twenty":-7.780249,"median":-5.151816,"eighty":-3.42923,"marketCap":20196712},{"date":"2026-01-16","current":-3.660807,"twenty":-7.780249,"median":-5.14469,"eighty":-3.42923,"marketCap":18531004},{"date":"2026-01-23","current":-3.208347,"twenty":-7.755842,"median":-5.119133,"eighty":-3.42923,"marketCap":16240655},{"date":"2026-01-30","current":-2.734499,"twenty":-7.661662,"median":-5.098261,"eighty":-3.381278,"marketCap":13842035},{"date":"2026-02-06","current":-2.426827,"twenty":-7.586816,"median":-5.063751,"eighty":-3.364521,"marketCap":12284598},{"date":"2026-02-13","current":-2.442869,"twenty":-7.51395,"median":-5.063751,"eighty":-3.27767,"marketCap":12365801},{"date":"2026-02-20","current":-2.303429,"twenty":-7.470914,"median":-5.048278,"eighty":-3.204892,"marketCap":11659957},{"date":"2026-02-27","current":-2.271757,"twenty":-7.452166,"median":-5.027001,"eighty":-3.156747,"marketCap":11499633},{"date":"2026-03-06","current":-2.698302,"twenty":-7.424045,"median":-5.019718,"eighty":-3.093003,"marketCap":13658807},{"date":"2026-03-13","current":-2.46796,"twenty":-7.400606,"median":-4.98699,"eighty":-3.049512,"marketCap":12492811},{"date":"2026-03-20","current":-2.529659,"twenty":-7.374048,"median":-4.948312,"eighty":-3.027281,"marketCap":12805132},{"date":"2026-03-27","current":-2.419423,"twenty":-7.358428,"median":-4.925987,"eighty":-2.995692,"marketCap":12247119},{"date":"2026-04-02","current":-2.380758,"twenty":-7.33968,"median":-4.899021,"eighty":-2.954226,"marketCap":12051399},{"date":"2026-04-10","current":-2.200475,"twenty":-7.311559,"median":-4.852143,"eighty":-2.923199,"marketCap":11985988},{"date":"2026-04-17","current":-2.403699,"twenty":-7.292811,"median":-4.845967,"eighty":-2.911648,"marketCap":13092947},{"date":"2026-04-24","current":-2.628935,"twenty":-7.263594,"median":-4.843588,"eighty":-2.858198,"marketCap":14319809},{"date":"2026-05-01","current":-2.220915,"twenty":-7.244298,"median":-4.831805,"eighty":-2.782532,"marketCap":12097326},{"date":"2026-05-08","current":-2.180035,"twenty":-7.217821,"median":-4.799555,"eighty":-2.739123,"marketCap":11874650},{"date":"2026-05-15","current":-1.805229,"twenty":-7.199074,"median":-4.787133,"eighty":-2.720186,"marketCap":10540732},{"date":"2026-05-22","current":-2.027078,"twenty":-7.170953,"median":-4.758877,"eighty":-2.696512,"marketCap":11836110},{"date":"2026-05-29","current":-1.932471,"twenty":-7.170953,"median":-4.74838,"eighty":-2.638077,"marketCap":11283701},{"date":"2026-06-05","current":-1.708789,"twenty":-7.161579,"median":-4.699647,"eighty":-2.62783,"marketCap":9977618},{"date":"2026-06-12","current":-1.680187,"twenty":-7.124084,"median":-4.685648,"eighty":-2.591975,"marketCap":9810610},{"date":"2026-06-18","current":-1.675786,"twenty":-7.124084,"median":-4.679404,"eighty":-2.58889,"marketCap":9784917},{"date":"2026-06-26","current":-1.374365,"twenty":-7.089251,"median":-4.661863,"eighty":-2.57116,"marketCap":8024917},{"date":"2026-07-02","current":-1.349796,"twenty":-7.079622,"median":-4.616471,"eighty":-2.529659,"marketCap":7881461},{"date":"2026-07-10","current":-1.356764,"twenty":-7.039719,"median":-4.598431,"eighty":-2.499514,"marketCap":7922143},{"date":"2026-07-17","current":-1.246389,"twenty":-7.030345,"median":-4.556506,"eighty":-2.476269,"marketCap":7277666},{"date":"2026-07-24","current":-1.092378,"twenty":-7.030345,"median":-4.471583,"eighty":-2.464669,"marketCap":6378395},{"date":"2026-07-31","current":-1.099712,"twenty":-7.030345,"median":-4.424013,"eighty":-2.432997,"marketCap":6421218},{"date":"2026-08-07","current":-1.430102,"twenty":-7.030345,"median":-4.370776,"eighty":-2.403935,"marketCap":8350367},{"date":"2026-08-10","current":-1.415434,"twenty":-7.030345,"median":-4.367964,"eighty":-2.401038,"marketCap":8264722}],"updateTime":1786467105071},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KAPA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654425140","title":"Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2654425140","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654425140?lang=en_us&edition=fundamental","pubTime":"2026-07-28 01:35","pubTimestamp":1785173716,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kairos Pharma, Ltd.. The associated price target remains the same w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/pantginis-reiterates-buy-on-env-105s-emerging-resistance-reversal-profile-and-bayer-collaboration-price-target-maintained-at-12-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/pantginis-reiterates-buy-on-env-105s-emerging-resistance-reversal-profile-and-bayer-collaboration-price-target-maintained-at-12-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","BK4139","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653722282","title":"Analysts Offer Insights on NA Companies: James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (KAPA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653722282","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653722282?lang=en_us&edition=fundamental","pubTime":"2026-07-24 01:10","pubTimestamp":1784826607,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (K...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-james-hardie-industries-plc-jhx-and-kairos-pharma-ltd-kapa-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-james-hardie-industries-plc-jhx-and-kairos-pharma-ltd-kapa-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","BK4139","KAPA","BK4011","NA","JHX","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653153768","title":"Kairos Pharma, Bayer partner on prostate cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2653153768","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653153768?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:58","pubTimestamp":1784725105,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) just unveiled an update. On July 16, 2026, Kairos Pharma entered into an investigator-initiated research agreement ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-bayer-partner-on-prostate-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-bayer-partner-on-prostate-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAPA","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653750717","title":"Kairos Pharma Partners with Bayer to Test Env-105 with Xofigo in Metastatic Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653750717","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653750717?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:35","pubTimestamp":1784723719,"startTime":"0","endTime":"0","summary":"Kairos Pharma partners with Bayer to test ENV-105 with Xofigo in metastatic prostate cancerKairos Pharma entered a strategic collaboration with Bayer to test ENV-105 with Bayer’s Xofigo in metastatic ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL9y48WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653755750","title":"Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance Xofigo Activity in Metastatic Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653755750","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653755750?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:35","pubTimestamp":1784723702,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUAYJVL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651463448","title":"Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105","url":"https://stock-news.laohu8.com/highlight/detail?id=2651463448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651463448?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:35","pubTimestamp":1784118922,"startTime":"0","endTime":"0","summary":"Kairos Pharma (KAPA) announced interim safety data from its ongoing Phase 1 clinical trial evaluating ENV-105 in combination with osimertinib in pa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-safety-data-from-phase-1-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-safety-data-from-phase-1-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","IDNA","MEDX","BBC","KAPA","GDOC","HYLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651463982","title":"Kairos Pharma Says Phase 1 Env-105 Plus Tagrisso Trial Shows no Grade 3+ Toxicities in 13 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2651463982","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651463982?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:35","pubTimestamp":1784118907,"startTime":"0","endTime":"0","summary":"Kairos Pharma says Phase 1 ENV-105 plus Tagrisso trial shows no Grade 3+ toxicities in 13 patientsKairos Pharma reported interim Phase 1 safety data for ENV-105 with AstraZeneca’s Tagrisso in EGFR-mut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL9M2cfC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651463351","title":"Kairos Pharma - no Grade 3 or Higher Adverse Events Observed in 13 Patients Treated with Env-105","url":"https://stock-news.laohu8.com/highlight/detail?id=2651463351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651463351?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:30","pubTimestamp":1784118609,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0II:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651146339","title":"Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of Env-105 in Egfr-mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2651146339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651146339?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:30","pubTimestamp":1784118609,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0II:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648956752","title":"Kairos Pharma Holds Annual Shareholder Meeting, Approves Reverse Stock Split Authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=2648956752","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648956752?lang=en_us&edition=fundamental","pubTime":"2026-07-01 05:20","pubTimestamp":1782854405,"startTime":"0","endTime":"0","summary":"Kairos Pharma holds annual shareholder meeting, approves reverse stock split authorizationKairos Pharma held its 2026 annual shareholder meeting on June 29, 2026.Shareholders ratified Weinberg & Compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL3nYwkS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640570921","title":"Kairos Pharma outlines mid-year oncology pipeline and funding plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2640570921","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640570921?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:37","pubTimestamp":1780576665,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) has provided an announcement. On June 4, 2026, Kairos Pharma issued a mid-year update highlighting a term sheet to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-outlines-mid-year-oncology-pipeline-and-funding-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-outlines-mid-year-oncology-pipeline-and-funding-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","BK4139","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640522157","title":"Kairos Pharma issues letter from CEO that recaps year, details plans for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640522157","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640522157?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:18","pubTimestamp":1780575508,"startTime":"0","endTime":"0","summary":"Kairos Pharma (KAPA) provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-issues-letter-from-ceo-that-recaps-year-details-plans-for-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-issues-letter-from-ceo-that-recaps-year-details-plans-for-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAPA","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157333","title":"Kairos Pharma signs term sheet to acquire worldwide rights to Celyn Therapeutics’ CL-741 cancer drug candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157333","media":"Reuters","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157333?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:15","pubTimestamp":1780575344,"startTime":"0","endTime":"0","summary":"Kairos Pharma signed a term sheet to acquire worldwide rights to CL-741 from privately held Celyn Therapeutics.CL-741 is an orally available, Phase 1-ready type IIb c-MET kinase inhibitor targeting EGFR-mutated NSCLC.Planned Phase 1 initiation in 2026; program also targets esophageal cancer, gastric cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL6xNyb8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kairos Pharma signs term sheet to acquire worldwide rights to Celyn Therapeutics’ CL-741 cancer drug candidate","news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640294152","title":"Kairos Pharma says shareholder letter now available to investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640294152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640294152?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:02","pubTimestamp":1780574538,"startTime":"0","endTime":"0","summary":"Kairos Pharma posted a mid-year 2026 letter to shareholders from CEO John Yu outlining priorities for the rest of the year.Letter highlights a term sheet with Celyn Therapeutics to acquire worldwide rights to CL-741, a Phase 1-ready oral type IIb c-MET inhibitor.Plan calls for initiating a Phase 1 CL-741 study in EGFR-mutated lung cancer; ENV-105 trials continue in prostate cancer, NSCLC results targeted by Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on June 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL39tg7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079453","title":"Kairos Pharma Highlights Clinical Programs at LD Micro","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079453","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079453?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:27","pubTimestamp":1779110871,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) has provided an update. On May 18, 2026, Kairos Pharma, Ltd. released a new investor presentation and made it avail...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-highlights-clinical-programs-at-ld-micro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-highlights-clinical-programs-at-ld-micro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LD","KAPA","BK4139","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635741674","title":"Analysts Offer Insights on Healthcare Companies: Kairos Pharma, Ltd. (KAPA), Integra Lifesciences (IART) and Biogen (BIIB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635741674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635741674?lang=en_us&edition=fundamental","pubTime":"2026-05-14 23:50","pubTimestamp":1778773845,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kairos Pharma, Ltd. (KAPA), Integra Lifesciences (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kairos-pharma-ltd-kapa-integra-lifesciences-iart-and-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kairos-pharma-ltd-kapa-integra-lifesciences-iart-and-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","LU0029874061.USD","LU0320765992.SGD","BIIB","BK4533","LU0234570918.USD","LU0889565916.HKD","KAIR","LU0128526141.USD","IE00B894F039.SGD","BK4532","IART","XBI","LU0109394709.USD","BK4581","BK4139","BK4585","KAPA","XLV","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BK4137","HCSG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635633759","title":"Kairos Pharma Q1 net loss widens to $1.65 million; no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2635633759","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635633759?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:22","pubTimestamp":1778707323,"startTime":"0","endTime":"0","summary":"Kairos Pharma posted a net loss of $1.65 million for the quarter ended March 31, 2026, widening from $1.26 million a year earlier.Operating loss widened to $1.69 million as operating expenses climbed to $1.69 million from $1.27 million.Research and development spending rose to $684,000 from $493,000, while general and administrative costs increased to $1.01 million from $773,000.Company raised $385,000 in gross proceeds from an at-the-market offering, signed a manufacturing services agreement with Patheon committing $783,000, and expanded its Lonza work scope by about $2 million for ENV105 Phase II supply preparation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL5V2k1k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710400.SGD","LU2125910179.SGD","LU2543165471.USD","LU2360108059.USD","LU1548497426.USD","LU1623119135.USD","LU2764262908.HKD","IE00BJJMRZ35.SGD","BK4581","LU0316494557.USD","KAPA","BK4548","LU1720051108.HKD","LU1854104046.USD","IE0009355771.USD","LU1989771016.USD","LU2211814178.USD","LU2298321311.HKD","LU0070302665.USD","LU2041044095.USD","LU0640476718.USD","IE00B19Z9505.USD","LU1064131342.USD","LU0320765489.SGD","LU2468319806.SGD","LU0342679015.USD","LU1983299246.USD","TMO","LU1720051017.SGD","LU1670628061.USD","LU1923622291.USD","LU2125910336.SGD","LU1023059063.AUD","LU1923622614.USD","IE00BQXX3D17.EUR","LU2764263203.CNY","LU0234572021.USD","IE00B2B36J28.USD","GB00BDT5M118.USD","LU0823416689.USD","LU1815333072.USD","LU2125909759.SGD","LU0528227936.USD","IE00BQXX3F31.USD","LU1633808545.USD","LU2092937221.SGD","LU2357305700.SGD","IE00B1BXHZ80.USD","IE0002141913.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634462535","title":"Kairos Pharma announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2634462535","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634462535?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:30","pubTimestamp":1778272254,"startTime":"0","endTime":"0","summary":"Kairos Pharma scheduled Annual Meeting of Shareholders to be held virtually on June 29, 2026.Meeting materials expected to be finalized and filed with SEC ahead of distribution to shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on May 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL6nLCdk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634462371","title":"Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2634462371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634462371?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:30","pubTimestamp":1778272201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA3DQ6V5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624658407","title":"Analysts Are Bullish on Top Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Actinium Pharmaceuticals (ATNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624658407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624658407?lang=en_us&edition=fundamental","pubTime":"2026-04-03 15:10","pubTimestamp":1775200225,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kairos Pharma, Ltd. (KAPA) and Actinium Pharmaceutic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-kairos-pharma-ltd-kapa-actinium-pharmaceuticals-atnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-kairos-pharma-ltd-kapa-actinium-pharmaceuticals-atnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BLSG","XBI","BK4588","BK4112","ATNM","BLSX","KAPA","BK4581","LU0029874061.USD","LU0128526141.USD","BK4137","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}]}}